Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.2.7 (
heparinase
)
1,270
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present studies examined the effects of heparin,
heparinase
, insulin or
insulin-like growth factor-I
on basic fibroblast growth factor actions on 5-ene-3 beta-hydroxysteroid dehydrogenase-isomerase activity of cultured immature rat Leydig cells. Treatment with basic fibroblast growth factor alone (0.025-20 ng/ml) for 2 days had a biphasic effect on enzyme activity, with lower concentrations (0.025-1 ng/ml) progressively inhibiting activity to approximately 20% of control, while higher concentrations (2.5-20 ng/ml) partially reversed the inhibitive effects. The inclusion of 10 micrograms/ml heparin, a concentration reported to inhibit growth factor binding to heparan sulfate proteoglycans, blocked the increase in enzyme activity elicited by higher growth factor concentrations, but had no effect on the progressive decline in activity due to lower concentrations. Concomitant treatment with
heparinase
I and III, which specifically hydrolyze heparan sulfate proteoglycans, had a similar effect. In addition, both insulin and
insulin-like growth factor-I
partially reversed the inhibition of enzyme activity due to treatment with 1 ng/ml basic fibroblast growth factor. These studies suggest that some basic fibroblast growth factor actions on cultured immature Leydig cells are mediated by binding to heparan sulfate proteoglycans, and that both insulin and
insulin-like growth factor-I
can reverse the inhibitive effects on 5-ene-3 beta-hydroxysteroid dehydrogenase-isomerase activity.
...
PMID:Evidence that biphasic effects of basic fibroblast growth factor on 5-ene-3 beta-hydroxysteroid dehydrogenase-isomerase activity in cultured immature Leydig cells are mediated by binding to heparan sulfate proteoglycans. 824 Sep 77
While extracellular acidification within solid tumors is well-documented, how reduced pH impacts regulation of
insulin-like growth factor-I
(
IGF-I
) has not been studied extensively. Because IGF-I receptor binding is affected by IGF binding proteins (IGFBPs), we examined how pH impacted IGFBP-3 regulation of
IGF-I
.
IGF-I
binding in the absence of IGFBP-3 was diminished at reduced pH. Addition of IGFBP-3 reduced
IGF-I
cell binding at pH 7.4 but increased surface association at pH 5.8. This increase in
IGF-I
binding at pH 5.8 corresponded with an increase in IGFBP-3 cell association. This, however, was not due to an increase in affinity of IGFBP-3 for heparin at reduced pH although both
heparinase
III treatment and heparin addition reduced IGFBP-3 enhancement of
IGF-I
binding. An increase in
IGF-I
binding to IGFBP-3, though, was seen at reduced pH using a cell-free assay. We hypothesize that the enhanced binding of
IGF-I
at pH 5.8 is facilitated by increased association of IGFBP-3 at this pH and that the resulting cell associated
IGF-I
is IGFBP-3 and not IGF-IR bound. Increased internalization and nuclear association of
IGF-I
at pH 5.8 in the presence of IGFBP-3 was evident, yet cell proliferation was reduced by IGFBP-3 at both pH 5.8 and 7.4 indicating that IGFBP-3-cell associated
IGF-I
does not signal the cell to proliferate and that the resulting transfer of bound
IGF-I
from IGF-IR to IGFBP-3 results in diminished proliferation. Solution binding of
IGF-I
by IGFBP-3 is one means by which
IGF-I
-induced proliferation is inhibited. Our work suggests that an alternative pathway exists by which
IGF-I
and IGFBP-3 both associate with the cell surface and that this association inhibits
IGF-I
-induced proliferation.
...
PMID:Insulin-like growth factor (IGF) binding protein-3 regulation of IGF-I is altered in an acidic extracellular environment. 1174 93